GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (ASX:OPT) » Definitions » Notes Receivable

Opthea (ASX:OPT) Notes Receivable : A$0.00 Mil (As of Dec. 2024)


View and export this data going back to 1991. Start your Free Trial

What is Opthea Notes Receivable?

Opthea's Notes Receivable for the quarter that ended in Dec. 2024 was A$0.00 Mil.


Opthea Notes Receivable Historical Data

The historical data trend for Opthea's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opthea Notes Receivable Chart

Opthea Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Opthea Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Opthea Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Opthea Notes Receivable Related Terms

Thank you for viewing the detailed overview of Opthea's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Opthea Business Description

Traded in Other Exchanges
N/A
Address
650 Chapel Street, Level 4, Suite 0403, South Yarra, VIC, AUS, 3141
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.